42 studies found for:    ovarian cancer recurrence | Open Studies | Exclude Unknown
Show Display Options
Rank Status Study
1 Recruiting Efficacy Study of Chemotherapy to Treat Ovarian Cancer Recurrence by Prolonging the Platinum Free Interval
Condition: Ovarian Cancer
Interventions: Drug: stealth liposomal doxorubicin;   Drug: carboplatin;   Drug: paclitaxel;   Drug: Topotecan;   Drug: Gemcitabine
2 Recruiting Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) in Ovarian Cancer Recurrence
Condition: First Recurrence of Ovarian Cancer
Interventions: Procedure: Secondary citoreduction;   Procedure: Hyperthermic intra-peritoneal chemotherapy (HIPEC)
3 Recruiting Bevacizumab Beyond Progression in Platinum Sensitive Ovarian Cancer
Condition: Recurrent Ovarian Cancer
Interventions: Drug: Bevacizumab;   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: pegylated liposomal doxorubicin;   Drug: Gemcitabine
4 Recruiting Whole-body Diffusion MRI for Staging, Response Prediction and Detecting Tumor Recurrence in Patients With Ovarian Cancer
Condition: Ovarian Carcinoma
Intervention: Other: Whole body diffusion-weighted MRI
5 Recruiting Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancer
Conditions: Ovarian Cancer;   Endometrial Cancer;   Fallopian Cancer;   Peritoneal Cancer
Interventions: Biological: E39 peptide vaccine;   Other: Clinical tracking for disease progression/recurrence
6 Recruiting Trial of Adjuvant FANG™ Vaccine for High Risk Stage III/IV Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Biological: FANG™
7 Recruiting Bevacizumab and Trabectedin +/- Carboplatin in Advanced Ovarian Cancer
Condition: Ovarian Epithelial Cancer Recurrent
Interventions: Drug: bevacizumab and trabectedin;   Drug: bevacizumab, trabectedin and carboplatin
8 Recruiting A Crossover Bioequivalence Study of Intravenously Administered ATI0918 and DOXIL/CAELYX in Patients With Ovarian Cancer
Conditions: Ovarian Cancer;   Malignant Female Reproductive System Neoplasm;   Cancer;   Ovarian Tumor;   Ovarian Epithelial Cancer Recurrent
Interventions: Drug: DOXIL/CAELYX;   Drug: ATI-0918
9 Not yet recruiting H.O.P.E: Helping Ovarian Cancer Patients Cope
Conditions: Platinum-resistant Ovarian Cancer;   Recurrent Ovarian Cancer;   Palliative Care
Interventions: Other: Structured Palliative Care;   Other: Usual Care
10 Recruiting Prognostic and Predictive Value of HE4 Biomarker in Metastatic Ovarian Cancer
Condition: Metastatic Ovarian Cancer
Intervention: Other: Experimental arm
11 Recruiting Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma
Conditions: Ovarian Cancer;   Adverse Effects
Intervention: Drug: Sunitinib
12 Recruiting Pelvic and Aortic-cava Lymphadenectomy Randomized for Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Procedure: ovarian cancer surgery
13 Recruiting Secondary Debulking Surgery +/- Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Procedure: Secondary debulking;   Procedure: secondary debulking with intraperitoneal chemotherapy
14 Not yet recruiting Low Dose Cyclophosphamide +/-- Nintedanib in Advanced Ovarian Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer
Intervention: Drug: BIBF 1120
15 Recruiting Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)?
Conditions: Ovarian Epithelial Cancer Recurrent;   Fallopian Tube Carcinoma;   Primary Peritoneal Carcinoma
Interventions: Procedure: Secondary Cytoreductive Surgery;   Drug: Salvage Chemotherapy
16 Recruiting Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer
Conditions: Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Intervention: Procedure: Tumor Debulking Surgery (surgery in recurrent ovarian disease)
17 Recruiting Phase II Study of NGR-hTNF in Combination With Doxorubicin in Platinum-resistant Ovarian Cancer
Condition: Ovarian Cancer
Interventions: Drug: NGR-hTNF;   Drug: Pegylated liposomal doxorubicin;   Drug: Doxorubicin
18 Recruiting LYmphadenectomy After NeoAdjuvant Chemotherapy
Condition: Advanced Ovarian Cancer (Stage III or IV) After Neoadjuvant Chemotherapy
Intervention: Procedure: Systematic pelvic and aortic lymphadenectomy
19 Recruiting Trial of Active Immunotherapy With Globo H-KLH (OPT-822/821) in Women Who Have Non-Progressive Ovarian Cancer
Condition: Ovarian Cancer
Intervention: Biological: OPT-822/OPT-821
20 Recruiting A Randomized Study of Safety and Efficacy of Pazopanib and Gemcitabine in Persistent or Relapsed Ovarian Cancer
Conditions: Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
Interventions: Drug: Gemcitabine;   Drug: pazopanib

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years